Profil
Christopher Taylor is currently working as the VP-Investor Relations and Corporate Communications at Agios Pharmaceuticals, Inc. He previously worked as the Vice President-Investor Relations & Communications at Alaunos Therapeutics, Inc. and as the VP-Investor Relations & Corporate Communications at Codiak BioSciences, Inc. from 2020 to 2023.
Postes actifs de Christopher Taylor
| Sociétés | Poste | Début |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Investor Relations Contact | - |
Anciens postes connus de Christopher Taylor
| Sociétés | Poste | Fin |
|---|---|---|
| CODIAK BIOSCIENCES | Investor Relations Contact | 01/06/2023 |
| ALAUNOS THERAPEUTICS, INC. | Investor Relations Contact | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| ALAUNOS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
